In addition to beneficial effects on CVD and reduction in LDL-c levels, proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9-i) appeared to ameliorate NAFLD/NASH [122]. Here, PCSK9 is linked to metabolic dysfunction-associated steatohepatitis.